End-of-day quote
Taiwan S.E.
03:30:00 26/06/2024 am IST
|
5-day change
|
1st Jan Change
|
73.3
TWD
|
+2.81%
|
|
+3.68%
|
-3.04%
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
14,968
|
8,616
|
12,275
|
11,197
|
48,245
|
65,793
|
Enterprise Value (EV)
1 |
15,382
|
9,305
|
9,941
|
9,669
|
42,690
|
58,795
|
P/E ratio
|
-15.5
x
|
-7.91
x
|
-7.63
x
|
-17
x
|
-67.7
x
|
-56.5
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
1,18,99,31,875
x
|
3,20,75,60,164
x
|
10,21,78,74,951
x
|
EV / Revenue
|
-
|
-
|
-
|
1,02,75,67,156
x
|
2,83,82,52,273
x
|
9,13,10,45,630
x
|
EV / EBITDA
|
-21.1
x
|
-10.3
x
|
-14.5
x
|
-17.1
x
|
-71.4
x
|
-56.2
x
|
EV / FCF
|
-44.2
x
|
-25
x
|
-22.3
x
|
-25
x
|
-54.4
x
|
-137
x
|
FCF Yield
|
-2.26%
|
-3.99%
|
-4.49%
|
-4.01%
|
-1.84%
|
-0.73%
|
Price to Book
|
16
x
|
13.5
x
|
3.4
x
|
3.89
x
|
7.34
x
|
7.59
x
|
Nbr of stocks (in thousands)
|
2,46,631
|
2,85,756
|
6,52,901
|
6,52,901
|
6,54,612
|
7,41,746
|
Reference price
2 |
60.69
|
30.15
|
18.80
|
17.15
|
73.70
|
88.70
|
Announcement Date
|
30/04/18
|
22/04/19
|
20/04/20
|
19/04/21
|
03/03/22
|
26/05/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
|
-
|
-
|
-
|
9.41
|
15.04
|
6.439
|
EBITDA
1 |
-730
|
-903.2
|
-687.4
|
-564.7
|
-598
|
-1,046
|
EBIT
1 |
-843.7
|
-1,014
|
-795.2
|
-678.1
|
-731.9
|
-1,158
|
Operating Margin
|
-
|
-
|
-
|
-7,205.72%
|
-4,866.15%
|
-17,977.12%
|
Earnings before Tax (EBT)
1 |
-897.4
|
-1,032
|
-828.9
|
-660.2
|
-739.7
|
-1,145
|
Net income
1 |
-898.5
|
-1,032
|
-829.8
|
-660.2
|
-740.5
|
-1,150
|
Net margin
|
-
|
-
|
-
|
-7,016.2%
|
-4,923.12%
|
-17,866.64%
|
EPS
2 |
-3.922
|
-3.811
|
-2.464
|
-1.011
|
-1.089
|
-1.570
|
Free Cash Flow
1 |
-347.7
|
-371.5
|
-445.9
|
-387.3
|
-784.7
|
-428.4
|
FCF margin
|
-
|
-
|
-
|
-4,116.06%
|
-5,216.78%
|
-6,653.27%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
30/04/18
|
22/04/19
|
20/04/20
|
19/04/21
|
03/03/22
|
26/05/23
|
Fiscal Period: December |
2022 Q2
|
---|
Net sales
1 |
1.768
|
EBITDA
|
-
|
EBIT
1 |
-278
|
Operating Margin
|
-15,726.02%
|
Earnings before Tax (EBT)
|
-
|
Net income
|
-
|
Net margin
|
-
|
EPS
|
-
|
Dividend per Share
|
-
|
Announcement Date
|
22/08/22
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
414
|
690
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
2,333
|
1,528
|
5,555
|
6,998
|
Leverage (Debt/EBITDA)
|
-0.5669
x
|
-0.7638
x
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-348
|
-372
|
-446
|
-387
|
-785
|
-428
|
ROE (net income / shareholders' equity)
|
-147%
|
-125%
|
-39%
|
-20.3%
|
-14.7%
|
-14.5%
|
ROA (Net income/ Total Assets)
|
-25.2%
|
-30.2%
|
-16.3%
|
-11.3%
|
-8.18%
|
-8.49%
|
Assets
1 |
3,571
|
3,420
|
5,077
|
5,818
|
9,052
|
13,549
|
Book Value Per Share
2 |
3.800
|
2.240
|
5.530
|
4.410
|
10.00
|
11.70
|
Cash Flow per Share
2 |
2.230
|
1.370
|
4.000
|
0.2300
|
8.180
|
9.740
|
Capex
1 |
20.6
|
43.2
|
50.2
|
51
|
204
|
69.6
|
Capex / Sales
|
-
|
-
|
-
|
542.44%
|
1,358.57%
|
1,081.43%
|
Announcement Date
|
30/04/18
|
22/04/19
|
20/04/20
|
19/04/21
|
03/03/22
|
26/05/23
|
|
1st Jan change
|
Capi.
|
---|
| -3.04% | 1.63B | | +25.50% | 52.73B | | +37.49% | 39B | | -9.14% | 38.52B | | +28.00% | 30.38B | | -12.26% | 26.39B | | +10.46% | 26.08B | | +45.00% | 14.15B | | +32.34% | 12.6B | | -6.14% | 11.51B |
Other Biotechnology & Medical Research
|